×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease ...
Yahoo Finance
Yahoo Finance · Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company. Zevra...
5 months ago
Zevra Therapeutics completes Acer acquisition in $91m deal
Pharmaceutical Technology
Zevra Therapeutics has concluded the takeover of complete outstanding shares of Acer Therapeutics in a deal valued at $91m.
5 months ago
Zevra Therapeutics Acquires Acer Therapeutics
Contract Pharma
Zevra Therapeutics Acquires Acer Therapeutics. Acquisition includes OLPRUVA, an FDA-approved treatment for UCDs. ... Zevra Therapeutics, Inc., a...
5 months ago
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
GlobeNewswire
Proposed acquisition of Acer for $15M in Zevra stock plus Contingent Value Rights (CVRs) and Zevra's purchase of Acer's secured debt in...
8 months ago
Why Is Acer Therapeutics (ACER) Stock Up 85% Today?
InvestorPlace
Acer Therapeutics (ACER) stock is taking off on Thursday after the company announced an acquisition deal with Zevra Therapeutics (ZVRA).
8 months ago
Zevra is buying rare disease compatriot Acer for $91M
Fierce Pharma
Zevra Therapeutics has jumped the queue to become a commercial rare disease company with a new acquisition and the addition of a marketed...
8 months ago
Zevra adds Edsivo for vEDS to its rare disease portfolio in new...
Ehlers-Danlos News
Zevra Therapeutics acquires Acer Therapeutics, adding Edsivo for the treatment of vascular EDS to its clinical pipeline in rare diseases.
7 months ago
Acer Therapeutics (NASDAQ:ACER) Skyrockets 136% on Acquisition News - TipRanks.com
Tipranks
Acer Therapeutics (NASDAQ:ACER) shares are up over 136% at the time of writing today after the pharmaceutical company agreed to be acquired...
8 months ago
Acer Therapeutics, funded almost entirely by its own CEO, has weeks to live - Boston Business Journal
The Business Journals
A Newton biotech has just a few weeks of cash runway as it struggles to commercialize its recently approved urea cycle disorder drug.
8 months ago
Acer stabilizes with Zevra merger and Relief deal
BioWorld MedTech
Zevra Therapeutics Inc. will acquire Acer Therapeutics Inc. in a $91 million deal that combines two companies with expertise in rare...
8 months ago